SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
Active, not recruiting · NCT03614949 · Registry updated 2026-04-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 2 | 2026-04-01 | NCT03614949 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| H. Lee Moffitt Cancer Center and Research Institute | 162 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | United States | 32 |
| Ohio State University - OSUMC - Wexner Medical Center | Hilliard | United States | 1 |